Reply to email dated 23/04/2025 regarding Additional detail required for Corporate Announcement filed under Regulation 30 of SEBI (LODR) Regulation 2015
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
In a single board meeting on April 16, 2025, Chemo Pharma Laboratories saw seven key personnel exit at once. CEO Bhavin Sheth, CFO Ashok Somani, Company Secretary Unnatti Jain, and four directors (including three independent directors Shanta Somani, Mathura Prasad Sharma, Toby Antony, and Nandkumar Pareek) all resigned effective the same day. The company simultaneously appointed Ruchit Mehta as new Managing Director and CEO, Utsav Trivedi as CFO, Bhawna Rajput as new Company Secretary, and Sarvagya Goel and Shilpi Chopra as Non-Executive Independent Directors. All appointments are subject to shareholder approval.
This is an unusually sweeping leadership change for a small-cap pharma company — the CEO, CFO, and most of the board were replaced in one go, which may raise governance and continuity concerns for shareholders. Investors should watch for the shareholder approval outcome and any further clarity on the strategic direction under the new MD Ruchit Mehta.